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Abstract	
Objec ve: To examine the associa on of cTnI eleva on and risk of serious cardiac complica ons and in-hospital 
death in Hispanics with an AMI residing in Puerto Rico. Material and methods: Pa ents from the Puerto Rico Heart 
A ack Study hospitalized during 2007, 2009, and 2011 with a validated AMI diagnosis and with cTnI obtained 
within the first 24-hours of admission were included for analysis. cTnI increase >10µg/L was defined as high. We 
u lized logis c regression modeling to examine the associa on of cTnI levels and serious cardiac complica ons 
(atrial/ventricular tachycardia/fibrilla on, atrioventricular block, papillary muscle rupture, heart failure and 
cardiogenic shock) and death while controlling for poten al confounders. Results:  Approximately 52% (1,542) 
pa ents met the inclusion criteria. The overall mean age was 66 ± 14 years and 848 (55%) were men. A er adjus ng 
for age, gender and comorbidi es, pa ents with high cTnI levels had almost five- mes the odds of developing 
serious cardiac complica ons (OR=4.8, 95%CI=3.2-7.0; p<0.001) and twice the odds of dying (OR=2.1, 95%CI=1.3-
3.3; p=0.002) than those with lower cTnI levels.  Conclusion: Puerto Ricans with AMI and cTnI levels >10µg/L at 
admission had significantly higher odds of serious cardiac complica ons and death than those with lower cTnI 
levels.
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	Niveles	altos	de	troponina	e	incremento	de	riesgo	de	complicaciones	
cardiacas	serias	y	muerte	en	puertorriqueños	con	infarto	agudo	del	
miocardio
Resumen	
Obje vo: Examinar la asociación de niveles de TncI y riesgo de complicaciones cardiacas graves y muerte 
hospitalaria en puertorriqueños hospitalizados con IAM. Material y métodos: Pacientes del Puerto Rico Heart 
A ack Study  hospitalizados durante 2007, 2009 y 2011 con diagnós co confirmado de IAM y TncI  obtenido dentro 
de las primeras 24-horas de admisión fueron incluidos para el análisis. Niveles de TncI >10µg/L fueron definidos 
como altos. U lizamos un modelo de regresión logís ca mul variado para examinar la asociación entre niveles de 
TncI y complicaciones cardiacas graves (taquicardia/fibrilación atrial/ventricular, bloqueo atrio-ventricular, rotura 
del músculo papilar, arresto cardíaco, choque cardiogénico) y muerte ajustando por posibles factores de confusión. 
Resultados: Aproximadamente 52% (1,542) de pacientes cumplieron los requisitos de inclusión. El promedio 
general de edad fue 66±14 años y 848 (55%) fueron hombres. Después de ajustar por edad, género y 
comorbilidades, pacientes con niveles de TncI altos tuvieron casi cinco veces más riesgo de desarrollar 
complicaciones cardiacas graves (OR=4.8, 95%CI=3.2-7.0;p<0.001) y dos veces más riesgo de morir (OR=2.1, 
95%CI=1.3-3.3; p=0.002) comparado con aquellos con niveles de TncI <10µg/L. Conclusión: Puertorriqueños 
hospitalizados con IAM y niveles de TncI >10µg/L durante las primeras 24h de admisión tuvieron riesgo 
significa vamente mayor de presentar complicaciones cardiacas graves y de morir que aquellos con niveles de TncI 
más bajos en el mismo período. 
Palabras clave: terapia trombolí ca; hispano; acidente cerebrovascular
Introduction	
Acute myocardial infarc on (AMI) is the single leading 
cause of death in the United States and in Puerto Rico. 
More than 1 million individuals suffer an AMI every 
year in the United States (1), and approximately one-
thousand new cases were registered annually in the 
Puerto Rico Heart A ack Study (2). Previous studies 
have demonstrated that abnormal eleva on of 
conven onal troponin levels (cTnI), i.e., above 
threshold values in pa ents with AMI is an important 
predictor of mortality and provides important 
prognos c value (3, 4). In addi on, abnormal 
conven onal cTnI levels have been associated with 
increased electrical complica ons (auricular and 
ventricular tachycardia/fibrilla on, atrioventricular 
block), and mechanical complica ons (ventricular 
septum, papillary muscle and/or free wall rupture, 
heart failure (HF), and cardiogenic shock) (5). 
However, there are contradictory findings, among 
studies examining the associa on of the degree of 
cTnI eleva on and the risk of serious cardiac 
complica ons and in-hospital mortality (6). In 
addi on, there is a paucity of informa on on the 
associa on of high cTnI levels and complica ons and 
dead among Hispanic popula ons hospitalized with 
an AMI. The purpose of this study is to evaluate the 
associa on of cTnI levels and serious cardiac 
(electrical and mechanical) complica ons and in-
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hospital mortality among Hispanic living in Puerto 
Rico who have been hospitalized with an AMI.  
Material	and	Methods
We reviewed the medical records of Puerto Rican 
pa ents hospitalized for possible AMI at 21 academic 
and/or non-teaching medical, and nonmilitary centers 
with emergency room capability. According to the 
United States Bureau Census, the Puerto Rican 
popula on is considered mostly Hispanic and in 2010 
there were 3,700,000 individuals residing on the 
Island (7). A complete lis ng with informa on on all 
hospital discharges during study years 2007, 2009, 
and 2011 with Interna onal Classifica on of Diseases, 
Ninth Revision, Clinical Modifica on (ICD-9-CM) code 
410 in the principal and/or secondary diagnosis 
posi on, and related acute and chronic coronary 
disease ICD-9 rubrics (i.e., 412 –old MI, 413 –angina 
pectoris, 414 – other forms of chronic CHD, and 786.5 
–chest pain), was obtained from each of the 
par cipa ng hospitals. Once the computerized 
discharge diagnosis printouts were obtained from 
each par cipa ng hospital, the appropriate ICD-9-CM 
codes for CHD were reviewed for purposes of case 
valida on. The list of selected medical records to be 
reviewed was given to medical record department 
personnel at each par cipa ng hospital. Trained nurse 
and physician abstractors reviewed the medical 
records of all iden fied pa ents mee ng the clinical 
criteria for AMI developed by the World Health 
Organiza on, which includes a clinical history 
sugges ve of AMI, serum enzyme eleva ons, and 
serial ECG findings during hospitaliza on. Since this 
study was focused on pa ents with an ini al (incident) 
AMI, records of previous hospitaliza ons for CHD 
were reviewed if the hospital chart indicated that the 
present hospitaliza on was not the first for CHD. 
Pa ents with ECG changes indica ve of prior MI (old 
Q-waves on ECG) or prior documented MI (confirmed 
by medical  records corresponding to prior 
hospitaliza ons) were excluded. Pa ents who 
developed AMI secondary to an interven onal 
procedure or surgery, other than for the treatment of 
an acute coronary event, were excluded. Autopsy 
confirma on of recent onset MI sa sfied the study 
inclusion criteria, irrespec ve of the other diagnos c 
criteria. Pa ents who were ini ally admi ed to the 
emergency department and stabilized in one hospital, 
and transferred therea er to another hospital, were 
only counted once. 
We u lized a standardized data collec on form 
developed in the Worcester Heart A ack Study (8), 
which was adapted for use in Puerto Rico u lizing a 
non-concurrent prospec ve design approach. Study 
abstractors created an online electronic database with 
more than 750 variables that included pa ent's 
demographic characteris cs (i.e., age, gender, 
municipality of residence); acute presen ng 
symptoms (i.e., chest pressure/discomfort, arm/hand 
numbness, indiges on/abdominal, back, chest, jaw, 
le /right arm and shoulder pain, cough, shortness of 
breath/dyspnea, fever, palpita on/rapid heart rate, 
swea ng/ diaphoresis, vomi ng); coronary risk 
fa c to rs  a n d  co m o r b i d i   e s  ( i . e . ,  d i a b ete s , 
hypertension, hyperlipidemia, smoking, angina, 
stroke, heart failure); physiologic parameters (i.e., 
heart rate, blood pressure, lipid profile, serum 
crea nine or glucose findings); AMI type (i.e., ST-
eleva on AMI (STEMI) or non-ST-eleva on AMI 
(NSTEMI)); use of invasive coronary procedures (i.e., 
cardiac catheteriza on/thrombolysis, percutaneous 
coronary interven ons (PCI), and coronary bypass 
surgery (CABG)); and hospital survival status. Data 
were captured electronically u lizing the REDCap™ 
web applica on exclusively designed for research 
studies that allows secure online management of 
surveys and databases (9). 
During the PRHAS years (2007, 2009, and 2011) only 
conven onal (not high-sensi vity) troponin along 
with CK and CK-MB levels were u lized for AMI 
biomarker diagnosis in Puerto Rico. In addi on, 
although the decision limit for myocardial injury was 
established at the 99th percen le of the assay, each 
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laboratory reported cTnI levels according to their 
manufacturer's cutoff limits. Because of the poten al 
varia ons and imprecision in the analy cal 
performance (accuracy and precision) of the troponin 
assay during this study  me span (2007 - 2011), along 
w i t h  t h e  p o s s i b l e  u   l i za   o n  o f  d i ffe r e n t 
manufacturers (Abbo , Beckman, Dade, Ortho, and 
Siemens), pla orms (Architect 2000i, Access 2, 
Dimension Vista, Vitros Eci, and ADVIA Centaur) for 
cTnI, and their coefficient of varia on (CV) at 99th 
percen le (from 10% - 20%), we sorted the reported 
values of cTnI (in µg/L) obtained during the first 24 
hours of admission and dichotomized in two 
categories: high if the actual cTnI values were at least 
10 µg/L, and low if the actual cTnI values ranged from 
above the upper normal limit and below the 10 µg/L. 
We defined serious cardiac electric complica ons if 
any of the following terms were men oned in the 
medical record: auricular tachycardia or fibrilla on, 
ventricular tachycardia or fibrilla on, and or 
atrioventricular block.  Serious cardiac mechanical 
complica ons were considered if any of the following 
terms were men oned in the medical record: 
ventricular septum, papillary muscle and/or free wall 
rupture, heart failure, and cardiogenic shock). 
Hypertension, hyperlipidemia, diabetes mellitus and 
smoking status were included as comorbidi es if any 
of them were ever men oned in the medical record. In 
addi on, the  me since onset of symptoms and  me 
of arrival to the emergency department was defined 
as “ me since symptoms onset”. 
Only those cases with cTnI levels obtained within the 
first 24 hours of admission were included in the 
analysis. Differences in the distribu on of con nuous 
variables, such as cTnI levels and age between men 
and women, were examined by using Student t-test. 
2
Chi  was u lized to test differences in the propor on 
of pa ents having high cTnI levels, e.g., >10 µg/L and 
serious electrical and mechanical complica ons and 
in-hospital deaths. In addi on, ini al bivariate logis c 
regression analysis was u lized to calculate the odds 
ra os (OR) with 95% confidence intervals of those 
pa ents with high cTnI levels and the presence of 
complica ons and death during hospitaliza on. All 
variables showing sta s cal  s ignificance in 
associa on with high cTnI levels, in addi on to 
comorbidi es, age and gender were incorporated into 
a mul variate logis c regression model. For Student t-
test and Chi2 analysis, sta s cal significance was 
established at the 0.05 level or if the confidence 
® 
intervals did not overlap. STATA version 13.0 (10) was 
used for analysis. 
Results
During the study period, conven onal cTnI levels were 
the most common diagnos c biomarker u lized in 
Puerto Rico. Of the 2,962 pa ents included in the 
PRHAS, 52% (1,542) had cTnI levels measured during 
the first 24 hours of admission. The final study 
popula on comprised 848 men (55%) and 694 women 
with an overall mean age of 66 ± 14 years. The mean 
cTn I levels was 19.5 ± 2.4 SD µg/L, with men having 
significantly higher cTnI levels (25.3 + 1.9 µg/L) than 
women (19.5 + 1.4 µg/L), p=0.02. Three out of four 
pa ents had a cTnI levels > 10 µg/L. 
Table 1 shows a breakdown of selected demographics 
and comorbidi es by cTnI level for subjects 
hospitalized with an AMI. Pa ents with high CTnI 
levels were approximately two years older than their 
counterparts with low cTnI levels (p<0.001). The 
propor on of men with high cTnI levels was 5% higher 
than the propor on of men with low cTnI levels 
(p=0.012). The percentage of hypertensive pa ents 
among those with high cTnI levels exceeded by 5.7% 
the propor on of hypertensive pa ents in the group 
with low cTnI levels (p=0.05). Diabetes mellitus was 
more common among pa ents with high cTnI values 
by  3%.  The  rates  of  current  smoking  and 
complica ons following hospitaliza ons were 
approximately 5% and 3% significantly higher, 
respec vely, among pa ents with high cTnI levels 
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compared to those with low cTnI levels. There was no 
sta s cally significant difference found in  me since 
symptoms onset, or hyperlipidemia between those 
with abnormal versus those with low cTnI levels. 
Table 1. Distribu on of selected demographics and 
comorbidi es by troponin level in Puerto Rican 
pa ents hospitalized with acute myocardial infarc on 
in 2007, 2009, 2011 (N=1,542)
¹Sig. Calculated using Chi square tes ng for categorical variables and t 
tes ng for con nuous variables. Significance expressed as p values. Time 
since symptoms onset, risk factors (hypertension, hyperlipidemia, 
complica ons and current smoking status are considered comorbidi es.
²Complica ons: Atrial fibrilla on, ventricular tachycardia, ventricular 
fibrilla on, shock and/or asystole during hospitaliza on for acute 
myocardial infarc on.
Table 2 shows the results of bivariate analysis 
between cTnI levels, age, gender, hypertension, and 
in-hospital complica ons and death. Among pa ents 
who died during hospitaliza on, the propor on of 
those who had high cTnI levels exceeded that of 
pa ents with low cTnI levels by 4% (p<0.001). Pa ents 
who died were, on average, nine years older than 
those who survived to discharge (p=0.016). 
Approximately 2% less men than women died during 
hospitaliza on (p=0.014). The propor on of 
hypertensive pa ents was 2.6% lower among those 
who died, as compared to the group of pa ent who 
survived. Approximately 22% of pa ents who died 
had a documented complica on, as compared to the 
group of pa ents who survived and experienced no 
complica ons during hospitaliza on (p<0.001). 
Variables not found to be significantly associated with 
in-hospital mortality were  me since symptoms 
onset, hyperlipidemia, diabetes, and smoking status.
Table 2. Associa on between comorbidi es and 
survival status in Puerto Rican pa ents hospitalized 
with acute myocardial infarc on in 2007, 2009, 2011 
(N=1,542)
1
Sig. Calculated using Chi square tes ng for categorical variables and t 
tes ng for con nuous variables, unless otherwise specified. Significance 
expressed as p values. Time since symptoms onset, risk factors 
(hypertension, hyperlipidemia, complica ons and current smoking status 
are considered comorbidi es. 
2
Complica ons: Atrial fibrilla on, ventricular tachycardia, ventricular 
fibrilla on, shock and/or asystole during hospitaliza on for acute 
myocardial infarc on.
Table 3 depicts a comparison of the unadjusted and 
adjusted analysis between poten al confounders 
(age, gender, hypertension, and in-hospital 
complica ons) and in-hospital mortality. Unadjusted 
analysis showed that pa ents with high cTnI levels 
we re  2 . 4    m e s  m o re  l i ke l y  to  d i e  d u r i n g 
hospitaliza on than pa ents with low cTnI levels (OR 
2.4, 95% CI 1.6-3.7). For every one addi onal year of 
age, unadjusted analysis revealed a 10% increase in 
the odds of in-hospital death (OR 1.1, 95% CI 1.0-1.1). 
Men had 40% greater odds of dying than women 
 
Characteris c Survival Status 
N (%) 
Sig1 
 
Dead 180 (11.7) 
Alive 1,362 
(88.3) 
 
Troponin (cTnI)    <0.001 
High (>10 µg/L)   131 (7.3) 1,279 (92.7)  
Low (<10 µg/L) 49 (3.2) 83 (96.8)  
Age – years, mean (+/-
SD) 
75.7 (+/-11.9) 66.5 (+/-13.8) 0.016 
Gender   0.014 
Men 71 (4.6) 777 (95.4)   
Women 109 (7.1) 585 (92.9)  
Time since symptoms 
onset – minutes, mean 
(+/-SD) 
843.4 (+/-
587.7) 
619.56 (+/-
584.1) 
0.394 
Hypertension 79 (5.1) 119 (7.7) 0.027 
Hyperlipidemia 99 (6.4) 83 (5.4) 0.23 
Diabetes mellitus 97 (6.3) 77 (5.0) 0.18 
Complica ons2 353 (22.9) 0 <0.001 
Current Smoking 74 (4.8) 88 (5.7) 0.53 
 
Characteris c cTnI Level Sig1 
 >10 µg/L 
N (%) 
<10 µg/L 
N (%) 
 
Age – years, mean (+/- 
SD) 
67.8 (+/-14.0) 65.4 (+/-13.3) <0.001 
Gender (men) 627 (56.8) 221 (51.4) 0.012 
Time since symptoms 
onset – minutes, mean 
(+/- SD) 
614.2 (+/- 
583.3) 
678.0 (+/- 
593.8) 
0.277 
Hypertension 925 (60.5) 324 (54.8) 0.05 
Hyperlipidemia 326 (29.2) 115 (30.2) 0.623 
Diabetes mellitus 540 (49.1) 177 (45.8) 0.011 
Complica ons2 91 (8.3) 20 (5.2) 0.005 
Current smoking 175 (16.1) 43 (11.3) 0.002 
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according to the unadjusted analysis (OR 1.4, 95% CI 
1.1-1.9). Pa ents with hypertension were almost 
twice as likely to die as compared to pa ents without 
hypertension (OR 1.9, 95% CI 1.1-3.6). A er adjus ng 
for age, gender, and in-hospital complica ons, 
pa ents with high cTnI levels were s ll approximately 
twice as likely to die while hospitalized as pa ents 
with low cTnI levels (OR 2.1, 95% CI 1.3-3.3). A er 
adjus ng for confounders, a one-year increase in age 
s ll resulted in 10% greater odds of in-hospital death 
(OR 1.1, 95% CI 1.0-1.1). Hypertensive pa ents held 
twice the odds of dying (OR 2.0, 95% CI 1.1-3.6). Per 
the adjusted analysis, those who experienced 
complica ons were five  mes more likely to die during 
their hospital course than pa ents without 
complica ons (OR 4.8, 95% CI 3.2-7.0). A er adjus ng 
for age, gender, hypertension, and in-hospital 
complica ons, there was no sta s cally significant 
associa on between gender and in-hospital mortality 
(OR 1.3, 95% CI 0.95-1.84).
Table 3. Unadjusted and adjusted associa on 
between troponin level and in-hospital mortality in 
Puerto Rican pa ents hospitalized with acute 
myocardial infarc on in 2007, 2009, 2011 (N=1,542)
1
Sig. Calculated using Chi square tes ng for categorical variables and t 
tes ng for con nuous variables. Significance expressed as p values. 
2
Complica ons: Atrial fibrilla on, ventricular tachycardia, ventricular 
fibrilla on, shock and/or asystole during hospitaliza on for acute 
myocardial infarc on.
Discussion
AMI is diagnosed by increased levels of cardiac 
biomarkers, together with (a) symptoms, (b) 
electrocardiographic changes, or (c) imaging findings, 
consistent with acute myocardial ischemia. Although 
current guidelines recommend the use of the 99th 
percen le of a reference popula on with coefficient 
of variance ≤10% as a cut-off value for the diagnosis of 
AMI, un l recently, the cTnI assays were insufficiently 
precise to define reliably the 99th percen le of a 
normal reference popula on (11). Further, the 
current normal reference popula on levels for 
troponins are absent for Hispanic popula ons. The 
delayed rise in circula ng concentra ons of cTn a er 
ini al symptoms presenta on of ischemia was 
another major limita on of conven onal assays. 
These analy cal weaknesses have been successfully 
overcome by the development of newer assays, the so 
called high-sensi ve troponins. 
Findings of this study conducted among Hispanics 
hospitalized in Puerto Rico are consistent with 
previous studies that have demonstrated that cTnI 
above threshold values in pa ents with AMI is an 
important predictor of mortality and provides 
important prognos c value (3,4) In addi on, these 
findings also suggest that there is a sta s cally 
significant associa on between cTnI above threshold 
values in pa ents with AMI and increased electrical 
and mechanical complica ons, which is consistent 
with results of the published literature (5).
Conclusion
In summary, Puerto Rican pa ents with incident AMI 
who have high cTnI levels in the first 24 hours are twice 
more l ikely  to progress  to ser ious cardiac 
complica ons and in-hospital death. This associa on 
persisted despite adjus ng for pa ent age 
comorbidi es.  To our knowledge this is the first study 
to evaluate troponin levels as a predictor of AMI 
complica ons and death in Puerto Rico.  cTnI levels 
above (>10µg/L) may detect Puerto Ricans with AMI 
who may benefit from more intensive monitoring for 
preven on and early treatment of HF, papillary 
muscle rupture and death. 
 
Characteris c  
Unadjusted 
OR  
95% CI  Sig1  
Adjusted  
OR  
95% CI  Sig1  
Troponin 
(high)
 2.4
 
(1.6-3.7)
 
<0.001
 
2.1
 
(1.3-3.3)
 
0.002
 
Age (years)
 
1.1
 
(1.0-1.1)
 
<0.001
 
1.1
 
(1.0-1.1)
 
<0.001
 
Gender (men)
 
1.4
 
(1.1-1.9)
 
0.017
 
1.3
 
(1.0-1.8)
 
0.101
 
Hypertension
 
1.9
 
(1.1-3.6)
 
0.008
 
2.0
 
(1.1-3.6)
 
<0.001
 
Complica ons2
 
5.7
 
(4.0-8.2)
 
<0.001
 
4.8
 
(3.2-7.0)
 
<0.001
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Strengths and Limita ons
Several researchers have reported a significant 
associa on of troponin levels and mortality in the 
intensive care unit se ngs (4-6) These findings bring 
new insight to the prognos c value high levels of cTnI 
(>10µg/L) in Hispanic pa ents with incident AMI. In 
addi on, all our cases were independently validated, 
and our study was performed in 21 different hospitals, 
which enhance the heterogeneity of the sample.  This 
study has at lease the following limita ons: 
Approximately half of the records did not have cTnI 
values collected within the 24 hours a er admission, 
and reported in the medical records. The selected >10 
µg/L cut off point selected to define high cTnI levels, 
although jus fied to control for the diverse use of 
biomarker assay manufacturers and reported cutoff 
levels at each of the 21 par cipa ng laboratories, it is 
arbitrary. Although we did not specifically validate the 
electric or mechanical complica ons men oned in the 
medical record with the actual EKG pa ern or 
echocardiogram finding, it would be very unlikely that 
“cardiac arrest” or “ventricular fibrilla on” or 
“ventricular free-wall rupture” would be men oned in 
the medical/nursing notes without having occurred.  
Finally, finings from this study should be generalized 
with cau on to other popula ons.
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